Larimar Therapeutics, Inc.
LRMRNASDAQHealthcare● Active
$3.10
$-0.07(-2.21%)
Market Cap$265291961
P/E Ratio—
52W High$6.42
52W Low$2.22
Larimar Therapeutics, Inc. (LRMR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LRMR · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.31
Est. -$0.53 · +41.5%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
LRMR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.39 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 14, 2026 | -$0.53 | -$0.31 | +41.5% | — | — | — |
| ▼ Q1 FY2026 | Mar 19, 2026 | -$0.44 | -$0.73 | -65.9% | — | — | — |
| ▼ Q4 FY2025 | Nov 5, 2025 | -$0.39 | -$0.61 | -56.4% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.47 | -$0.41 | +12.8% | — | — | — |
| ▼ Q2 FY2025 | Apr 30, 2025 | -$0.42 | -$0.46 | -9.5% | — | — | — |
| ▼ Q1 FY2025 | Mar 24, 2025 | -$0.29 | -$0.45 | -55.2% | $0.00B | — | — |
| ▲ Q4 FY2024 | Oct 30, 2024 | -$0.37 | -$0.24 | +35.1% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.39
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Beat
EPS Actual
-$0.31
EPS Est.
-$0.53
EPS Surpr.
+41.5%
Revenue
—
Q1 FY2026
Mar 19, 2026Miss
EPS Actual
-$0.73
EPS Est.
-$0.44
EPS Surpr.
-65.9%
Revenue
—
Q4 FY2025
Nov 5, 2025Miss
EPS Actual
-$0.61
EPS Est.
-$0.39
EPS Surpr.
-56.4%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.41
EPS Est.
-$0.47
EPS Surpr.
+12.8%
Revenue
—
Q2 FY2025
Apr 30, 2025Miss
EPS Actual
-$0.46
EPS Est.
-$0.42
EPS Surpr.
-9.5%
Revenue
—
Q1 FY2025
Mar 24, 2025Miss
EPS Actual
-$0.45
EPS Est.
-$0.29
EPS Surpr.
-55.2%
Revenue
$0.00B
Q4 FY2024
Oct 30, 2024Beat
EPS Actual
-$0.24
EPS Est.
-$0.37
EPS Surpr.
+35.1%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.34 | $-0.34 | $-0.34 | 1 |
| Q3 FY2027 | $-0.40 | $-0.40 | $-0.40 | 1 |
| Q2 FY2027 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Q1 FY2027 | $-0.46 | $-0.46 | $-0.46 | 1 |
| Q4 FY2026 | $-0.47 | $-0.47 | $-0.47 | 1 |
| Q3 FY2026 | $-0.53 | $-0.43 | $-0.33 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +41.5% | $4.10 | $3.89 | -5.12% |
| ▼ Q1 FY2026 | Mar 19, 2026 | -65.9% | $4.30 | $4.47 | +3.95% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -56.4% | $3.80 | $3.22 | -15.26% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +12.8% | $3.72 | $4.26 | +14.52% |
| ▼ Q2 FY2025 | Apr 30, 2025 | -9.5% | $2.39 | $2.65 | +10.88% |
| ▼ Q1 FY2025 | Mar 24, 2025 | -55.2% | $2.54 | $2.28 | -10.24% |
| ▲ Q4 FY2024 | Oct 30, 2024 | +35.1% | $7.78 | $8.46 | +8.74% |
| ▼ Q3 FY2024 | Aug 7, 2024 | -6.3% | $7.65 | $7.15 | -6.54% |
Q2 FY2026-5.12%
Report Date
May 14, 2026
EPS Beat/Miss
+41.5%
Price Before
$4.10
Price After
$3.89
Q1 FY2026+3.95%
Report Date
Mar 19, 2026
EPS Beat/Miss
-65.9%
Price Before
$4.30
Price After
$4.47
Q4 FY2025-15.26%
Report Date
Nov 5, 2025
EPS Beat/Miss
-56.4%
Price Before
$3.80
Price After
$3.22
Q3 FY2025+14.52%
Report Date
Aug 14, 2025
EPS Beat/Miss
+12.8%
Price Before
$3.72
Price After
$4.26
Q2 FY2025+10.88%
Report Date
Apr 30, 2025
EPS Beat/Miss
-9.5%
Price Before
$2.39
Price After
$2.65
Q1 FY2025-10.24%
Report Date
Mar 24, 2025
EPS Beat/Miss
-55.2%
Price Before
$2.54
Price After
$2.28
Q4 FY2024+8.74%
Report Date
Oct 30, 2024
EPS Beat/Miss
+35.1%
Price Before
$7.78
Price After
$8.46
Q3 FY2024-6.54%
Report Date
Aug 7, 2024
EPS Beat/Miss
-6.3%
Price Before
$7.65
Price After
$7.15
Avg Beat Reaction+6.05%
Avg Miss Reaction-3.44%
Beat Rate3 / 8 quarters
Largest Move-15.26% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LRMR ends December
Larimar Therapeutics, Inc. (LRMR) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.31 — beating the analyst consensus of $-0.53 by +41.5%. The next LRMR earnings date is expected around September 1, 2026.
Each quarter, investors track LRMR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LRMR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LRMR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LRMR earnings · 5 questionsLarimar Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. LRMR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LRMR historically reports after market close (AMC).
LRMR earnings datewhen is LRMR earningsLRMR next earnings datewhen does LRMR report earningsLRMR earnings calendar
▸ Source: FMP · Larimar Therapeutics, Inc. SEC filings · US GAAP · Larimar Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026